[go: up one dir, main page]

WO1995018636A2 - Conjugues de medicaments a ciblage hepatocytaire - Google Patents

Conjugues de medicaments a ciblage hepatocytaire Download PDF

Info

Publication number
WO1995018636A2
WO1995018636A2 PCT/US1995/000448 US9500448W WO9518636A2 WO 1995018636 A2 WO1995018636 A2 WO 1995018636A2 US 9500448 W US9500448 W US 9500448W WO 9518636 A2 WO9518636 A2 WO 9518636A2
Authority
WO
WIPO (PCT)
Prior art keywords
conjugate
crosslinker
ligand
covalently bonded
carrier molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/000448
Other languages
English (en)
Other versions
WO1995018636A3 (fr
Inventor
Robert Plourde Jr
Ellen Carmichael
George L Spitalny
Mark A Findeis
Michael F Ernst
Brett Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TargeTech Inc
Original Assignee
TargeTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TargeTech Inc filed Critical TargeTech Inc
Priority to AU16791/95A priority Critical patent/AU1679195A/en
Priority to JP7518699A priority patent/JPH09510696A/ja
Priority to EP95908490A priority patent/EP0737077A1/fr
Priority to CA002180348A priority patent/CA2180348A1/fr
Publication of WO1995018636A2 publication Critical patent/WO1995018636A2/fr
Publication of WO1995018636A3 publication Critical patent/WO1995018636A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Cette invention concerne des conjugués utilisés pour cibler un agent thérapeutique sur une cellule comprenant des récepteurs d'asialoglycoprotéine. Ces conjugués comprennent un agent thérapeutique et un ligand destiné au récepteur d'asialoglycoprotéine, ledit agent thérapeutique et ledit ligand étant liés par un agent de pontage. L'agent de pontage peut être un agent de réticulation, une molécule porteuse polyfonctionnelle ou un agent de réticulation et une molécule porteuse polyfonctionnelle. Dans une forme de réalisation préférée l'agent thérapeutique est un analogue nucléosidique ou de la colchicine et le ligand est de l'asialoorosomucoïde, de l'arabinogalactane ou un tri-(N-acétyle galactosamine aminohexyle glycoside) amide de tyrosyl(glutamyl)-glutamate. Les agents de réticulation préférés comprennent les dérivés d'aminoacyle, les dérivés de carboxyacyle, le phosphate, les peptides et les agents de réticulation labiles par réduction. Les molécules porteuses polyfonctionnelles comprennent les acides polyamino et les polysaccharides. On peut utiliser les conjugués de cette invention pour cibler un agent thérapeutique sur une cellule, par exemple pour inhiber la réplication d'ADN viral dans un hépatocyte infecté par un virus.
PCT/US1995/000448 1994-01-11 1995-01-11 Conjugues de medicaments a ciblage hepatocytaire Ceased WO1995018636A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU16791/95A AU1679195A (en) 1994-01-11 1995-01-11 Hepatocyte-targeted drug conjugates
JP7518699A JPH09510696A (ja) 1994-01-11 1995-01-11 肝細胞を標的とする薬物結合体
EP95908490A EP0737077A1 (fr) 1994-01-11 1995-01-11 Conjugues de medicaments a ciblage hepatocytaire
CA002180348A CA2180348A1 (fr) 1994-01-11 1995-01-11 Conjugues de medicaments a ciblage hepatocytaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18020794A 1994-01-11 1994-01-11
US08/180,207 1994-01-11

Publications (2)

Publication Number Publication Date
WO1995018636A2 true WO1995018636A2 (fr) 1995-07-13
WO1995018636A3 WO1995018636A3 (fr) 1995-08-10

Family

ID=22659615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/000448 Ceased WO1995018636A2 (fr) 1994-01-11 1995-01-11 Conjugues de medicaments a ciblage hepatocytaire

Country Status (5)

Country Link
EP (1) EP0737077A1 (fr)
JP (1) JPH09510696A (fr)
AU (1) AU1679195A (fr)
CA (1) CA2180348A1 (fr)
WO (1) WO1995018636A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021452A3 (fr) * 1995-12-14 1997-10-09 Advanced Magnetics Inc Promedicaments macromoleculaires d'analogues de nucleotides
US6296844B1 (en) 1995-09-27 2001-10-02 The General Hospital Corporation Asialocytokines and treatment of liver disease
WO2011086143A3 (fr) * 2010-01-14 2011-12-01 Glaxo Group Limited Molécules ciblant le foie
EP2657246A4 (fr) * 2010-10-27 2014-04-02 Public Univ Corp Yokohama City Modulateur de l'activité de l'adénylate cyclase
WO2017093993A1 (fr) * 2015-12-03 2017-06-08 Biosight Ltd. Conjugués de cytarabine pour le traitement du cancer
CN108610384A (zh) * 2018-05-31 2018-10-02 沈阳药科大学 基于肠道mct1载体蛋白设计的前药及其制备方法
US11104698B2 (en) 2015-12-03 2021-08-31 Biosight Ltd. Salts of conjugates for cancer therapy
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
JP5750209B2 (ja) * 2007-03-16 2015-07-15 アプタ バイオサイエンス リミテッド 機能性分子、機能性分子合成用アミダイド、及び標的物質解析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2082507A1 (fr) * 1990-05-11 1991-11-12 George Y. Wu Protection ciblee contre les cytotoxines
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6296844B1 (en) 1995-09-27 2001-10-02 The General Hospital Corporation Asialocytokines and treatment of liver disease
WO1997021452A3 (fr) * 1995-12-14 1997-10-09 Advanced Magnetics Inc Promedicaments macromoleculaires d'analogues de nucleotides
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
WO2011086143A3 (fr) * 2010-01-14 2011-12-01 Glaxo Group Limited Molécules ciblant le foie
CN102791293A (zh) * 2010-01-14 2012-11-21 葛兰素集团有限公司 肝靶向分子
US9096632B2 (en) 2010-10-27 2015-08-04 Public University Corporation Yokohama City University Modulator of activity of adenylate cyclase
EP2657246A4 (fr) * 2010-10-27 2014-04-02 Public Univ Corp Yokohama City Modulateur de l'activité de l'adénylate cyclase
WO2017093993A1 (fr) * 2015-12-03 2017-06-08 Biosight Ltd. Conjugués de cytarabine pour le traitement du cancer
US11058701B2 (en) 2015-12-03 2021-07-13 Biosight Ltd. Cytarabine conjugates for cancer therapy
US11104698B2 (en) 2015-12-03 2021-08-31 Biosight Ltd. Salts of conjugates for cancer therapy
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
CN108610384A (zh) * 2018-05-31 2018-10-02 沈阳药科大学 基于肠道mct1载体蛋白设计的前药及其制备方法
WO2019228319A1 (fr) * 2018-05-31 2019-12-05 沈阳药科大学 Promédicament basé sur la conception de protéine porteuse mct1 intestinal et son procédé de préparation
CN108610384B (zh) * 2018-05-31 2022-02-22 沈阳药科大学 基于肠道mct1载体蛋白设计的前药及其制备方法

Also Published As

Publication number Publication date
WO1995018636A3 (fr) 1995-08-10
CA2180348A1 (fr) 1995-07-13
EP0737077A1 (fr) 1996-10-16
JPH09510696A (ja) 1997-10-28
AU1679195A (en) 1995-08-01

Similar Documents

Publication Publication Date Title
US5981507A (en) Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
Di Stefano et al. A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate
US5106951A (en) Antibody conjugates
US6083926A (en) Water soluble vitamin B12 receptor modulating agents and methods related thereto
ES2245805T3 (es) Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes.
Nishikawa et al. Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting
US20050250679A1 (en) Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
US20030119724A1 (en) Ligands to enhance cellular uptake of biomolecules
WO1988009823A1 (fr) Derives amines d'antibiotiques d'anthracycline et leurs conjugues anticorps
WO2000074721A1 (fr) Vitamine pour therapie a double ciblage
WO1995018636A2 (fr) Conjugues de medicaments a ciblage hepatocytaire
US20120213732A1 (en) Targeted delivery of antiviral compounds through hemoglobin bioconjugates
Di Stefano et al. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route
US20030103934A1 (en) Drugs having long-term retention in target tissue
Di Stefano et al. Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier
WO1997014711A9 (fr) Agents de modulation des recepteurs de la vitamine b¿12?
Fiume et al. Targeting of antiviral drugs by coupling with protein carriers
Wu et al. A new N-acetylgalactosamine containing peptide as a targeting vehicle for mammalian hepatocytes via asialoglycoprotein receptor endocytosis
US20080260691A1 (en) Prodrugs of Ribavirin with Improved Hepatic Delivery
US20050220754A1 (en) Vitamin directed targeting therapy
JPH0633320B2 (ja) ラクトサミン化ヒトアルブミンとアデニン―９―β―Ｄ―アラビノフラノシド５′モノホスフェートの結合体の製造方法
Fiume et al. Hepatocyte targeting of antiviral drugs coupled to galactosyl-terminating glycoproteins
CA2566874C (fr) Administration ciblee de composes antiviraux au moyen de bioconjugues a base d'hemoglobine
US6291638B1 (en) Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them
JPH01211530A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2180348

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995908490

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995908490

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995908490

Country of ref document: EP